STREPTOCOCCI OF THE VIRIDANS GROUP are reported to be the most common bacterial etiologic agents of infective endocarditis, constituting about 30 to 40% of cases.`Penicillin alone or in combination with streptomycin is the preferred antimicrobial therapy for these patients. 5 '-" The use of short-term combined penicillin-streptomycin therapy for infective endocarditis caused by penicillin-sensitive streptococci was first suggested more than 25 years ago;5-7, 12 but it has not gained wide accep- tance.
In a prospective study, we treated 33 patients who had infective endocarditis caused by viridans streptococci for two weeks with intramuscular procaine penicillin plus streptomycin. Our experience with these patients is the subject of this report.
Material and Methods
Only patients with infective endocarditis caused by streptococci of the viridans group were enrolled in our prospective study. Our criteria for the diagnosis of infective enicity developed in one patient. One patient died two months after completion of antimicrobial therapy from sudden onset of severe congestive heart failure. Seven patients required cardiac valve replacement after completion of antimicrobial therapy. None died. We believe that this therapeutic regimen is effective antimicrobial therapy for infective endocarditis caused by viridans streptococci, irrespective of in vitro microbiologic data. docarditis were (1) at least two positive blood cultures with viridans streptococci on at least two separate days and (2) at least two of the following clinical signs fever, development of a new regurgitant murmur, newly developed splenomegaly, or peripheral embolic phenomenon.
Congestive heart failure was categorized according to criteria defined by the New York Heart Association. '3 Antimicrobial susceptibility tests were done by methods described elsewhere.14 Minimum inhibitory concentrations (MIC) and minimum bactericidal concentrations (MBC) were determined by serial dilution in broth in concentrations ranging from 100 to 0.09 ,ug/ml, and the results were expressed as the lowest concentration of antibiotic that killed at least 99.9% of the initial inoculum. Serum bactericidal tests (SBT) were determined during the third day of treatment on a serum sample taken one hour after intramuscular injection of procaine penicillin and streptomycin; the results were expressed as the greatest dilution of serum that killed at least 99.9% of the inoculum.
Relative penicillin resistance of viridans streptococci was defined as MIC > 0.1 ,ug/ml or MBC 2 3.12 ug/ml, as measured by broth dilution. Antimicrobial therapy in each patient was procaine penicillin G, 1.2 million units every 6 hours, and streptomycin, 500 mg every 12 hours, given intramuscularly for 14 days. The In table 2 , cases are distributed according to the class of congestive heart failure present at the initiation of antimicrobial therapy. Seven patients (21%) underwent cardiac valve replacement at various intervals after completion of antimicrobial therapy. All of these seven had evidence of previous infective endocarditis at the time of surgery, but gram-stained smears and cultures of the excised valves were negative in each case. None of the 24 patients with Class I or Class II congestive heart failure required cardiac valve replacement.
Mild vestibular toxicity occurred in one patient, a 78-year-old man with renal insufficiency. None of the remaining 32 patients had evidence of toxicity from antimicrobial therapy. The intramuscular injections were well tolerated.
Of the 33 patients in our study, one died. This patient died elsewhere about three weeks after completing antimicrobial therapy. In vitro microbiologic studies of the isolate from this patient were MIC _ 0.09 ,g/ml, MBC 3.12 ,g/ml, and SBT 1:8. This patient had infective endocarditis involving the mitral valve and Class III congestive heart failure. Cardiac valve replacement was suggested to her; however, she elected to return home without surgery. When she returned home, the congestive heart failure abruptly worsened and she died two days later. Antemortem blood cultures were reportedly negative. Postmortem examination performed elsewhere did not reveal evidence of active infective endocarditis; postmortem cultures of the previously infected mitral valve were reportedly negative.
Follow-up of the remaining 32 patients ranged from 2 months to 3.5 years. Blood cultures were negative at 1-and 2-month intervals after completion of antimicrobial therapy in these 32 patients, none of whom had clinical or laboratory signs of relapse of infective endocarditis.
Discussion
Hunter'2 originally suggested the use of short-term, combined penicillin-streptomycin treatment for patients with infective endocarditis caused by viridans streptococci. The rationale for this therapy was based on in vitro studies demonstrating synergy between penicillin and streptomycin against several isolates of viridans streptococci from patients with infective endocarditis. Recent studies have demonstrated conclusively that penicillin and streptomycin act synergistically against viridans streptococci.'1-57
In early reports, one of us (J.E.G.) reported only one In our prospective study, no relapses occurred among 33 patients treated for two weeks with intramuscular procaine penicillin and streptomycin. We are unaware of data comparing cure rates in patients with infective endocarditis caused by relatively penicillin-resistant strains of viridans streptococci. Some investigators28 suggest that when MIC values for viridans streptococci exceed 0.1 ,ug/ml, patients should receive antimicrobial therapy identical to that for enterococcal endocarditis. According to our criteria for relative penicillin resistance, nine of our 33 patients (27%) had infections with relatively penicillin-resistant microorganisms. Our data suggest that antimicrobial therapy in these patients need not differ from that of patients with penicillin-susceptible isolates. The in vitro susceptibility data of viridans streptococci are somewhat difficult to interpret because they are a heterogeneous group of bacteria which comprise at least six species with varying growth characteristics and CO2 requirements. Methods for testing their antimicrobial susceptibility are not standardized, and therefore, susceptibility data vary among laboratories. Moreover, in vitro susceptibility data may reflect interspecies differences and as yet incompletely studied intraspecies differences. In our experience, however, relative penicillin resistance did not affect mortality or relapse rates.
The low vestibular toxicity rate observed in our patients is similar to that reported by Tompsett and Hurst.'" Vestibular toxicity is more likely to occur in the elderly, in the presence of renal insufficiency, or with pre-existing vestibular dysfunction. We suggest that pretreatment audiograms and caloric determinations be obtained, and if signs of vestibular toxicity develop, or if pre-existing vestibular toxicity worsens, that streptomycin be discontinued. In patients who have renal insufficiency, we suggest that the dose of streptomycin be reduced and the serum streptomycin concentrations be monitored closely. Optimal serum concentration is estimated to be < 30 Aig/ml. Alternatively, patients who have renal insufficiency or pre-existing vestibular toxicity may be treated with 20 million units of intravenous penicillin alone, daily for 4 weeks. In these patients, the dose of penicillin may have to be adjusted according to the degree of renal insufficiency.
The mortality rate among our patients was low -3%. The single death resulted from sudden, severe worsening of pre-existing Class III congestive heart failure. In patients with severe congestive heart failure caused by infective endocarditis, cardiac valve replacement may be indicated. 29 The seven patients in our series who required cardiac valve replacement had Class III or IV congestive heart failure complicating the infective endocarditis. The operative risk of cardiac valve replacement in these patients appears to be related not to the presence of infective endocarditis but rather to the degree of congestive heart failure present at the time of surgery.30
Based on our data, we believe that intramuscular procaine penicillin, 1.2 million units every 6 hours, and streptomycin, 500 mg every 12 hours, daily for 2 weeks is effective antimicrobial therapy for infective endocarditis due to viridans streptococci in non-thrombocytopenic patients with adequate peripheral perfusion. This therapy appears to be efficacious irrespective of the MIC and MBC susceptibility data and appears to be at least as effective as treatment with penicillin alone for 4 weeks or combined penicillin and streptomycin therapy for 2 weeks followed by penicillin alone for an additional two weeks. The risk of vestibular toxicity associated with streptomycin use is small. The advantages of treatment for two weeks with intramuscular antimicrobials over treatment for four weeks with intravenous antimicrobials are clear -shortened hospitalization period with reduced cost to patients, more efficient use of hospital personnel and facilities, and avoidance of potential hazardous complications associated with the use of intravenous therapy. In our opinion a burden rests on those who advocate four weeks of therapy to demonstrate that this longer duration of treatment is more effectual, or less toxic, or more cost-effective than short-term therapy. 
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